COMPASS Pathways plc (NASDAQ:CMPS) Given Average Recommendation of “Buy” by Analysts

COMPASS Pathways plc (NASDAQ:CMPS) has been given an average recommendation of “Buy” by the six analysts that are covering the firm, MarketBeat reports. Six analysts have rated the stock with a buy rating. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $30.60.

A number of equities analysts recently weighed in on CMPS shares. Royal Bank of Canada reissued an “outperform” rating and issued a $18.00 price target on shares of COMPASS Pathways in a report on Wednesday, January 15th. HC Wainwright reduced their target price on shares of COMPASS Pathways from $60.00 to $45.00 and set a “buy” rating for the company in a research report on Thursday. Finally, Maxim Group dropped their price objective on COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, November 1st.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of CMPS. China Universal Asset Management Co. Ltd. purchased a new stake in shares of COMPASS Pathways during the fourth quarter worth $41,000. Flagship Harbor Advisors LLC purchased a new stake in COMPASS Pathways during the 4th quarter worth about $43,000. Wealthfront Advisers LLC bought a new position in COMPASS Pathways in the 4th quarter worth about $43,000. Conservest Capital Advisors Inc. grew its holdings in COMPASS Pathways by 28.9% during the 4th quarter. Conservest Capital Advisors Inc. now owns 13,363 shares of the company’s stock valued at $51,000 after buying an additional 3,000 shares in the last quarter. Finally, Simplify Asset Management Inc. bought a new stake in shares of COMPASS Pathways during the fourth quarter valued at about $54,000. 46.19% of the stock is owned by institutional investors.

COMPASS Pathways Stock Performance

Shares of COMPASS Pathways stock opened at $4.57 on Friday. The business’s fifty day simple moving average is $4.10 and its 200 day simple moving average is $5.49. The company has a current ratio of 8.91, a quick ratio of 8.91 and a debt-to-equity ratio of 0.15. COMPASS Pathways has a 12 month low of $3.16 and a 12 month high of $12.75. The firm has a market capitalization of $312.68 million, a P/E ratio of -2.08 and a beta of 2.28.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.